Entrada Therapeutics Inc (TRDA) Profitability Comparisons, Net Margin, Gross Margin, Tax rate, Cash Flow Margin Comparisons - CSIMarket
CSIMarket
 


Entrada Therapeutics Inc   (NASDAQ: TRDA)

Entrada Therapeutics Inc Profitability Comparisons

Select each Category to receive further Information




TRDA Profitability Ratio

Company Industry Sector S&P 500
Gross Profit Margin (Q2 MRQ) 0 % 68.81 % 54.17 % 38.76 %
Gross Margin (Q2 TTM) 0 % 69.19 % 55.83 % 38.1 %
Gross Profit Margin 5 Yr. Avg. - 62.89 % 52.78 % 32.58 %
EBITDA Margin (Q2 MRQ) 93.65 % 24.91 % 21.71 % 22.17 %
EBITDA Margin (Q2 TTM) 80.28 % 28.72 % 23.59 % 20.86 %
EBITDA Margin 5 Yr. Avg. - 50.51 % 34.72 % 23.59 %
Operating Margin (Q2 MRQ) -5007.02 % 17.3 % 16.59 % 16.03 %
Operating Margin (Q2 TTM) -3767.07 % 20.31 % 17.93 % 16.33 %
Operating Margin 5 Yr. Avg. - 15.4 % 14.73 % 16.68 %
Pre-Tax Profit Margin (Q2 MRQ) 0 % 13.66 % 10.94 % 13.94 %
Pre-Tax Profit Margin (Q2 TTM) 0 % 16.68 % 12.84 % 13.1 %
Pre-Tax Profit Margin 5 Yr. Avg. - 13.31 % 10.65 % 12.24 %
Net Margin (Q2 MRQ) -3.9 % 10.08 % 8.14 % 11.41 %
Net Margin (Q2 TTM) 722.98 % 13.07 % 9.96 % 10.76 %
Net Margin 5 Yr. Avg. - 6.08 % 6.13 % 9.62 %



Business Segment Profit Margin
 
Collaboration Service Revenue
  Explore Collaboration Service Revenue Segment  -
Recognition of Upfront and Milestone Payments
  Explore Recognition of Upfront and Milestone Payments Segment  -
Reportable
  Explore Reportable Segment  -
 

Company's Cashflow Profitability & Other



Profitability Ratios Company Industry Sector S&P 500
Free Cash Flow Margin (Q2 MRQ) -3616.26 % -0.01 % 0.21 % 1.39 %
Free Cash Flow Margin (Q2 TTM) -2875.14 % 17.25 % 14.06 % 9.36 %
Free Cash Flow Margin 5 Yr. Avg. - 20.92 % 15.77 % 13.91 %
Net Cash Flow Margin (Q2 MRQ) 0 % 0.02 % -0.02 % 0.13 %
Net Cash Flow Margin (Q2 TTM) 70.51 % -0.76 % 0.09 % 1.8 %
Net Cash Flow Margin 5 Yr. Avg. - 4.19 % 3.09 % 5.71 %
Effective Tax Rate (Q2 MRQ)